Supplementary Figures from Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC

Abstract

<p>Figure S1. Association between SPARC expression and distant metastasis free survival (RFS) in breast cancer patients with different PAM50 subtypes. Figure S2. Downregulation of SPARC expression in 4T1 and LM3 murine breast cancer cell lines. Figure S3. SPARC targeting inhibits primary tumor growth and lung metastasis establishment. Figure S4. SPARC-deficient cells exhibit a delay in cell cycle progression. Figure S5. Transcriptomic analysis of SPARC-deficient tumors revealed changes in cell-ECM interaction and immune response. Figure S6. Enforced expression of COX-2 in SPARC-deficient 4T1 cells partially restores cells capacity to grow as primary tumor. Figure S7. SPARC targeting impairs invasive capacity of breast cancer cells. Figure S8. Association between hS-PT and hS-ESM expression and distant metastasis free survival (RFS) in breast cancer patients with different PAM50 subtypes.</p>